Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;2(9):e481-e484.
doi: 10.1016/S2666-5247(21)00121-X. Epub 2021 Jul 27.

Genomic surveillance to combat COVID-19: challenges and opportunities

Affiliations
Review

Genomic surveillance to combat COVID-19: challenges and opportunities

Janet D Robishaw et al. Lancet Microbe. 2021 Sep.

Abstract

Although the development and increasingly widespread availability of effective and safe vaccines provides the greatest hope for the future recovery from the increasingly devastating COVID-19 pandemic, there are other preventive efforts that offer an immediate route to decreasing morbidity and mortality. Genomic surveillance is emerging as a vital necessity to achieve effective mitigation and containment. Since SARS-CoV-2 variants have already been detected, it is crucial to obtain reliable evidence about whether they are more contagious, virulent, or more resistant to the available COVID-19 vaccines well before they spread throughout the world. Genomic surveillance leverages applications of next-generation sequencing, creates the availability of whole genome data, and advances phylogenetic methods. These methods offer novel means to detect variants that are phenotypically or antigenically different. Genomic surveillance will facilitate greater early anticipation as well as initiation of effective strategies to mitigate and contain outbreaks of SARS-CoV-2 variants and other novel viruses.

PubMed Disclaimer

Conflict of interest statement

DLD reports that he is a consultant to the US National Institutes of Health, the US Food and Drug Administration, and the pharmaceutical and medical device industry on the design, monitoring, and analysis of clinical trials. He receives compensation for serving on several industry sponsored data and safety monitoring committees including AstraZeneca, Amgen, Actelion, Bristol Myers Squibb, DalCor, GlaxoSmithKline, Merck, Sanofi, Boston Scientific, Medtronic, Mesoblast, Intercept, Duke Clinical Research Institute, and Population Health Research Institute of Hamilton. He holds no stock in any pharmaceutical or device company. CHH reports that he serves as an independent scientist in an advisory role to investigators and sponsors as chair of data monitoring committees for Amgen, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, and Regeneron; serves as an independent scientist in an advisory role to the Collaborative Institutional Training Initiative; serves as legal counsel for Pfizer, the US Food and Drug Administration, and UpToDate; receives royalties for authorship or editorship of three textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital; has an investment management relationship with the West-Bacon Group within SunTrust Investment Services, which has discretionary investment authority; and does not own any common or preferred stock in any pharmaceutical or medical device company. All other authors declare no competing interests.

References

    1. Hennekens CH, George S, Adirim TA, Johnson H, Maki DG. The emerging pandemic of coronavirus and the urgent need for public health leadership. Am J Med. 2020;133:648–650. - PMC - PubMed
    1. Johns Hopkins University & Medicine Tracking—Johns Hopkins University Coronavirus Resource Center. https://coronavirus.jhu.edu/data
    1. Robson F, Khan KS, Le TK, et al. Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol Cell. 2020;79:710–727. - PMC - PubMed
    1. Vilar S, Isom DG. One year of SARS-CoV-2: how much has the virus changed? Biology (Basel) 2021;10:91. - PMC - PubMed
    1. Callaway E. The coronavirus is mutating—does it matter? Nature. 2020;585:174–177. - PubMed

Substances

Supplementary concepts